3 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Uncontrolled Hypertension: new trials by email Literature Review of Uncontrolled Hypertension trials Research Report on Uncontrolled Hypertension
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension VB19055 Dose A QD, VB19055 Dose B QD, VB19055 Dose C QD - Hypertension, Resistant Hypertension | Phase 2 | Not yet recruiting | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 240 | 2026-09-01 | 2026-09-22 |
| A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension SAL0140, Placebo - Uncontrolled Hypertension | Phase 2 | Recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 252 | 2025-12-09 | 2026-06-17 |
| A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension RTN-001, Matching placebo control - Uncontrolled Hypertension | Phase 2 | Recruiting | Retension Pharmaceuticals. Inc. | 280 | 2025-10-31 | 2026-10-02 |
| Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension iloperidone, Placebo - Hypertension, Uncontrolled Hypertension | Phase 2 | Recruiting | Vanda Pharmaceuticals | 240 | 2025-09-15 | 2026-02-27 |
| REGN5381 in Adult Participants With Uncontrolled Hypertension REGN5381, Placebo - Uncontrolled Hypertension | Phase 2 | Terminated | Regeneron Pharmaceuticals | 34 | 2025-04-16 | 2025-10-23 |
| A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension Baxdrostat, Placebo - Uncontrolled Hypertension | Phase 2 | Completed | AstraZeneca | 48 | 2024-06-10 | 2025-12-17 |
| A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease CIN-107, Placebo - Uncontrolled Hypertension, Chronic Kidney Diseases | Phase 2 | Completed | AstraZeneca | 195 | 2022-04-29 | 2025-05-20 |
| A Study of CIN-107 in Patients With Uncontrolled Hypertension CIN-107, Placebo - Uncontrolled Hypertension | Phase 2 | Completed | CinCor Pharma, Inc. | 249 | 2021-12-07 | 2023-08-01 |
| Rapid Renal Sympathetic Denervation for Resistant Hypertension II Renal Denervation (OneShot™ Renal Denervation System) - Resistant Hypertension, Uncontrolled Hypertension | Phase 2 / Phase 3 | Withdrawn | Medtronic Endovascular | 2013-09-01 | 2015-08-18 |
Hypertension (5) · Heart Murmurs (1) · Renal Insufficiency, Chronic (1) · Systolic Murmurs (1)
Cardiovascular Diseases (5) · Vascular Diseases (5) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Renal Insufficiency (1) · Signs and Symptoms (1) · Urogenital Diseases (1) · Urologic Diseases (1)
iloperidone (1)
AstraZeneca (2) · CinCor Pharma, Inc. (1) · Medtronic Endovascular (1) · Regeneron Pharmaceuticals (1) · Retension Pharmaceuticals. Inc. (1) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (1) · Vanda Pharmaceuticals (1) · Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (1)
United States (5) · China (2) · Italy (1) · United Kingdom (1)
Dierk Scheinert, MD (1) · Guiseppe Mancia, MD (1) · Jiguang Wang (1)